Pharmaceutical class: glucagon-like peptide 2 (GLP2) analogue that increases the absorptive surface of the intestinal epithelium. It is indicated for the treatment of short bowel syndrome (SBS-IF) in patients from 1 year of age, in a stable state after the period of intestinal adaptation.
Active compound: teduglutide
SmPC: click here for Revestive 1,25 mg
SmPC: click here for Revestive 5 mg
Revestive is available in 1,25 mg and 5 mg
Reimbursed indications of Revestive 1,25 mg
Reimbursed indications of Revestive 5 mg
PRICES
Price Revestive 1,25 mg: click here for information
Price Revestive 5 mg: click here for information
C-APROM/BE/REV/0026 – July 2021